AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$ALKS

Gaffin David Joseph sold $98K of ALKS

Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $48.01 on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gaffin David Joseph
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

Provides fresh data on insider activity; however, the amount is small and likely already priced in

02

Market read

Routine insider sale with minimal market impact

03

What to watch

Insider may be diversifying holdings; no change in company fundamentals

Relevance 2/10Novelty 4/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC regulations

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

EVP and CLO sold 2,034 shares for $97,652 via a 10b5-1 plan

Expected impact

Limited downward pressure, likely within normal volatility range

Evidence & confidence

The transaction is a routine 10b5-1 sale of under $100k; market impact is expected to be minimal

Market effects

Sector

None significant for the pharma sector

Regional

No broader regional effect

Global

Limited to Alkermes shareholders

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a bearish signal

Key entities

  • Officer
    Gaffin David Joseph

    EVP, CLO of Alkermes, reported sale of 2,034 shares

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALKS insider trading history →

Related articles

SEP 26
$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

insidermonkey.com2 min
SEP 24
$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

investing.com2 min
SEP 22
$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

medscape.com3 min
SEP 21
$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.

benzinga.com2 min